New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
07:10 EDTJAZZJazz Pharmaceuticals price target raised to $210 from $190 at UBS
UBS raised its price target on Jazz Pharmaceuticals to $210 from $190 on expectations for Xyrem sales growth, its lower tax rate and its strong balance sheet. UBS reiterated its Buy rating on Jazz Pharmaceuticals shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use